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DOI 10.1016/j.chembiol.2008.09.002With their unique ability to selectively at-
tack tumor cells, monoclonal antibodies
represent a major advance in the search
for a ‘‘magic bullet’’ against cancer. How-
ever, by targeting only tumor cells, these
molecules don’t fully exploit the body’s
own cancer-fighting mechanisms. Enter
the bispecific molecule, a monoclonal an-
tibody that binds both to tumor cells as
well as cells of the immune system, bring-
ing these two archenemies in close con-
tact. Preliminary clinical studies indicate
that this new type of antibody can unleash
powerful immune mechanisms such as
cytotoxic T cells against a tumor. When
used in conjunction with existing cancer
treatments such as surgery and chemo-
therapy, ‘‘bispecific antibodies could not
only help shrink a tumor, but could also
trigger cellular and humoral responses,’’
says Lawrence Lum, a clinical immunolo-
gist at the Karmanos Cancer Institute in
Detroit. ‘‘This could induce a long-term
immune response to the tumor.’’
The key to an effective anti-tumor im-
mune response are the body’s T lympho-
cytes. Abundant, ubiquitous, and agile,
T cells come equipped with two types of
powerful toxins for killing harmful cells:
perforins, which pierce cells, and gran-
zymes, which break up cellular proteins.
T cells can recognize potential tumor cells
by their surface antigens and destroy
them right away. They can kill multiple
times, recharging their toxins as needed.
They can amplify the attack by rapidly
proliferating at the tumor site. Finally, by
‘‘vaccinating’’ the immune system with
protein fragments from killed tumor cells,
they can establish a long-term anti-tumor
response. Despite all this, however, we do
get cancer. Tumor cells, with their high
Further, the T cell doesn’t die a
‘‘serial killing’’ spree.mutation rates, present a moving and
elusive target for T cells. The few that
manage to hide from the immune on-
slaught can grow into a tumor. ‘‘Any tumor
that you see is essentially a Darwinian
product,’’ says Richard Flavell, an immu-
nologist at the Yale University School of
Medicine. ‘‘It is made of cells that have
already succeeded in fighting off the
immune system.’’
Fortunately for us, the tumor’s disguise
is not perfect. Its cells almost always bear
some marker that sets them apart from
healthy tissue; much effort now goes
into identifying these markers and target-
ing them using monoclonal antibodies.
For instance, trastuzumab (Herceptin)
binds to and deactivates cells that carry
Her2/neu, a protein overexpressed in cer-
tain breast cancers. (Indeed, despite the
high cost of this drug—about $40,000
per year—some Canadian states now pro-
vide it as first-line therapy for eligible pa-
tients.) Such targeted remedies typically
have milder side effects than the more
brute-force drugs used in chemotherapy.
However, in many cases their ability to
kill or cripple tumor cells is limited. This is
where going bispecific could pay off—by
grabbing a tumor cell with one arm and
roping in an immune cell with the other,
the antibody could let the immune cell do
the killing. ‘‘The dream is to use bispecific
targeting to make T cells kill tumors more
effectively,’’ says Lum.
In pursuit of this goal, researchers have
been developing a wide range of bispe-
cific antibody molecules since the
1980s. Early designs retain the basic ‘‘Y’’
shape of natural antibody molecules:
stemming from a constant (Fc) region,
two variable arms branch out, and the
fter a single kill, but goes on aChemistry & Biology 15, September 22, 200tip (Fv region) of each arm binds to a differ-
ent molecule or epitope. (In contrast,
a conventional monospecific antibody
[mAb] such as trastuzumab has identical
Fv regions.) In a bispecific antibody
(bAb), one tip might target a tumor-asso-
ciated antigen and the other a molecule
on an immune cell. In 1991, the first mole-
cule of this type to undergo a clinical trial
targeted CD19, a protein found on certain
non-Hodgkin’s lymphoma cells, and CD3,
a marker found on T cells. To make this
molecule, researchers fused two types
of hybridoma cell: one designed to pro-
duce an anti-CD3 mAb and the other an
anti-CD19 mAb. Another early molecule
had the same T cell affinity but targeted
the EGP-2 protein found on some epithe-
lial tumors. Two more hybridoma-derived
bAbs, anti-CD3 3 anti-EPCAM for stom-
ach cancer and anti-CD3 3 anti-Her2/
neu for advanced breast cancer, are
now in advanced clinical trials.
Preclinical data shows that bispecific
antibodies do indeed help guide T cells
to tumors and may surpass conventional
mAbs in their antitumor effects. However,
results from clinical trials are mixed. Many
bAbs don’t work unless the patient’s im-
mune system is simultaneously given an
immune stimulator such as interleukin-2,
which increases the risk of complications.
Further, the molecules often attach them-
selves to circulating immune cells and
miss their tumor targets. Finally, immune
self-regulating mechanisms such as acti-
vation-induced cell death prevent T cells
activated by bAbs from surviving long
enough to do their job. As a result, many
bispecific antibodies work only under un-
realistically high ratios of immune cells to
tumor cells, ranging from 1:1 to nearly
100:1. ‘‘But as any pathologist who has
ever looked at a tumor can tell you, the ac-
tual ratio is more like 1:10 or even 1:1000,’’
says Louis Weiner, director of the Lom-
bardi Comprehensive Cancer Center at
Georgetown University and one of the
earliest designers of bispecific molecules.8 ª2008 Elsevier Ltd All rights reserved 877
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pecific antibodies suffer toxicities that
force investigators to use a less-than-
effective dose. In a 1995 clinical trial led
by Weiner, an anti-CD16 3 anti-HER2/
neu bAb used to treat advanced breast
cancer triggered a cytokine storm in
some patients. The molecule’s Fc region
is often to blame in such cases, as it can
activate a wide range of unwanted im-
mune cells. Consequently, this region is
absent in some of the newer molecules
such as MDX-H210, another bAb for
breast cancer; in a Phase I trial of this
Fc-less antibody completed in 2001, the
investigators found no dose-limiting
toxicities. Despite these improvements,
adverse immune effects remain a major
concern, says Weiner. ‘‘Until someone
can figure out how to deliver the bispecific
antibody to the tumor site without encoun-
tering and activating leukocytes on the
way, this will remain a problem,’’ he says.
To design safer and more effective
bAbs, some researchers have turned to
recombinant DNA technology. While
most of these designs are in the preclinical
stage, one format, termed BiTE (bispecific
T cell engager molecule), has advanced
further. In a recently completed Phase I
dose-escalation study of an anti-CD3 3
anti-CD19 BiTE for advanced non-Hodg-
kin’s lymphoma, the investigators re-
ported that all six patients receiving the
highest dose responded, including two
that had a complete response. Made by
Bethesda, Maryland-based Micromet,
a BiTE molecule is basically just a pair of
Fv regions joined together by a short, flex-
ible linker. Thanks to its small size and flex-
ibility, a BiTE can bring a T cell and a tumor
cell into close contact; once this so-called
immunological synapse forms, the T cell
can unleash its toxins on its target. Unlike
the case with earlier formats, a T cell
recruited by a BiTE molecule needs no
costimulation, according to Christian Itin,878 Chemistry & Biology 15, September 22,chief executive of Micromet. Further, the
T cell doesn’t die after a single kill, but
goes on a ‘‘serial killing’’ spree, he says.
As a result, the molecule works even at
extremely low concentrations. ‘‘It causes
enormously potent redirected lysis even
in the low picomolar range,’’ says Itin.
Despite these advances, working with
recombinant formats offers some chal-
lenges. The loss of the Fc domain could
reduce efficacy. Foreign peptides used
in the linkers could trigger an immune
reaction. Some molecules are unstable
or form insoluble aggregates in vivo.
The smaller ones typically circulate
only for a short time in the body – some-
times just an hour or less, compared to
several weeks for whole antibodies. And
toxicity remains a major concern, even if
animal studies suggest a molecule is
safe. ‘‘Mice are notoriously resistant to
cytokine storms,’’ says Weiner. ‘‘You
can be fooled into believing that some-
thing is a lot safer for people than it
actually is.’’
Many safety and efficacy issues with
bispecific antibodies arise because the
molecules either miss their target or hit
the wrong one. One way to improve both
safety and efficacy is to not administer
the bAb directly, but to use it to arm
T cells ex vivo and infuse them instead.
Studies by Lum and others show that
this method needs much lower antibody
doses than direct infusion. Since the
bAb molecules can’t make unwanted
bindings ex vivo, the threat of cytokine
storm diminishes. Further, it turns out
that arming T cells ex vivo prolongs their
effective life; this extra time allows them
to proliferate at the tumor site. ‘‘We dis-
covered, to our total surprise, that ex
vivo armed T cells did not die when they
engaged a tumor,’’ says Lum. ‘‘This not
only creates more effector cells to kill the
tumor but also vaccinates the endoge-
nous immune system against it.’’2008 ª2008 Elsevier Ltd All rights reservedEx vivo arming of T cells, however,
requires greater expertise and more ad-
vanced facilities than direct bAb infusion.
As a result, few large studies have em-
ployed this strategy so far. In a 1995
Phase II trial, 28 advanced ovarian cancer
patients were treated with T cells armed
with an anti-CD3 3 anti-OC/TR bAb.
Four patients had a complete response,
while three others had a partial response.
Side effects were mild to moderate and
transient, according to the researchers.
In ongoing clinical trials led by Lum, inves-
tigators are using T cells armed with anti-
CD3 3 anti-HER2/neu and anti-CD3 3
anti-CD20 bAbs to treat advanced breast
cancer and non-Hodgkin’s lymphoma,
respectively. Infusions of billions of armed
T cells seem to provoke only mild side ef-
fects such as chills and fever, says Lum. In
many patients, blood profiles indicate that
cancer cells are being killed and the im-
mune system is being primed to attack
the tumor, he adds.
As researchers continue to explore the
potential of bispecific antibodies, Lum
and Weiner caution against expecting
any bAb format or strategy to make tu-
mors vanish. Indeed, they question the
relevance of tumor shrinkage as a metric
in the case of immune-based therapies
such as bispecific antibodies. They argue
that such a therapy needs to kill only
a fraction of tumor cells to initiate antigen
processing and presentation, triggering
a long-term immune response. Clinical tri-
als that relate efficacy to tumor shrinkage
may thus undervalue immune-based ther-
apies. ‘‘The ultimate value of these thera-
pies may need to be measured not by how
much tumor is destroyed, but by how long
it’s controlled,’’ says Weiner. ‘‘In this
regard, a little bit of killing may be just as
effective as a lot of killing.’’
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